03.28.14
BioMedical Enterprises Inc. (BME) and CellRight Technologies Inc., both based in San Antonio, Texas, have formed a strategic partnership which began this year with BME’s launch of CellRight’s new Matrix OI 100 percent human osteoinductive (OI) bone morphogenetic protein (BMP) scaffold. BME’s expertise is in nitinol shape memory bone fixation devices, while CellRight Technologies makes regenerative osteobiologic and wound care scaffolds.
Matrix OI is designed to provide surgeons, hospitals and patients with a verified osteoinductive construct after sterilization. The osteoinductivity is confirmed by testing for five elements of osteoinductivity: chondrocytes, osteoblasts, bone marrow, cartilage and new bone using the proven and U.S. Food and Drug Administration recognized in-vivo Athymic Rat Model.
Matrix OI feature BME’s Press Fit Technology to make it compressible and flexible. It reportedly permits simple insertion and then anchors into irregularly shaped gaps and voids, mitigating the risk of migration. Its Stem Cell Containment (a patented feature) allows for up to 60 percent absorption of the grafts volume, according to the company.
“We are excited about our strategic partnership with CellRight Technologies,” said President and CEO of BME, Keith Peeples. “As a corporate partner, CellRight offers BME the expertise in orthobiologics that will position both companies for innovative product development and aggressive market penetration. Matrix OI is a whole new category of allograft tissue by confirming osteoinductivity after sterilization. Its design characteristics behave like a shape memory implant which fits nicely into our product portfolio.”
“We are equally excited about our strategic alliance with BME,” added Jesus Hernandez, president and CEO of CellRight Technologies. “This partnership is consistent with our long term goals of providing CellRight Technologies’ innovative osteoinductive grafting products to surgeons and their patients who suffer from debilitating defects caused by trauma and disease.”
BME makes nitinol metal implants for musculoskeletal fixation.
Matrix OI is designed to provide surgeons, hospitals and patients with a verified osteoinductive construct after sterilization. The osteoinductivity is confirmed by testing for five elements of osteoinductivity: chondrocytes, osteoblasts, bone marrow, cartilage and new bone using the proven and U.S. Food and Drug Administration recognized in-vivo Athymic Rat Model.
Matrix OI feature BME’s Press Fit Technology to make it compressible and flexible. It reportedly permits simple insertion and then anchors into irregularly shaped gaps and voids, mitigating the risk of migration. Its Stem Cell Containment (a patented feature) allows for up to 60 percent absorption of the grafts volume, according to the company.
“We are excited about our strategic partnership with CellRight Technologies,” said President and CEO of BME, Keith Peeples. “As a corporate partner, CellRight offers BME the expertise in orthobiologics that will position both companies for innovative product development and aggressive market penetration. Matrix OI is a whole new category of allograft tissue by confirming osteoinductivity after sterilization. Its design characteristics behave like a shape memory implant which fits nicely into our product portfolio.”
“We are equally excited about our strategic alliance with BME,” added Jesus Hernandez, president and CEO of CellRight Technologies. “This partnership is consistent with our long term goals of providing CellRight Technologies’ innovative osteoinductive grafting products to surgeons and their patients who suffer from debilitating defects caused by trauma and disease.”
BME makes nitinol metal implants for musculoskeletal fixation.